James Cleary, MD
Medical Oncology · Boston, MANPI 1922062397
Payments from drug & device makers
Across 285 payments — averaging $65,825 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$13.5M
- Merck$2.1M
- E.r. Squibb & Sons, L.L.C.$1.5M
- Servier Bioinnovation$428K
- Amgen$402K
- Foundation Medicine, Inc.$346K
- plus $466K from 18 others
Across 1 payment — averaging $2005.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Affaires Medicales$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 74 | $13,497,196 |
| Merck | 21 | $2,113,066 |
| E.r. Squibb & Sons, L.L.C. | 45 | $1,507,525 |
| Servier Bioinnovation | 51 | $428,407 |
| Amgen | 7 | $402,357 |
| Foundation Medicine, Inc. | 13 | $345,500 |
| Hoffmann-la Roche Limited | 15 | $138,380 |
| Roche Products Limited | 5 | $80,220 |
| Eli Lilly | 2 | $72,900 |
| Genentech, Inc. | 3 | $54,306 |
| Tesaro, Inc. | 2 | $28,044 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $20,650 |
| Taiho Oncology, Inc. | 7 | $11,914 |
| AstraZeneca | 6 | $11,050 |
| Partner Therapeutics, Inc. | 7 | $10,267 |
| Gilead | 2 | $9,992 |
| Beone Medicines USA, Inc. | 8 | $9,795 |
| Incyte Corporation | 6 | $6,005 |
| Blueprint Medicines Corporation | 1 | $4,032 |
| Astrazeneca UK Limited | 3 | $3,497 |
| Exelixis Inc. | 1 | $3,000 |
| Servier Pharmaceuticals LLC | 2 | $1,971 |
| F. Hoffmann-la Roche AG | 1 | $61 |
| Daiichi Sankyo Inc. | 1 | $53 |
How this compares
$18,760,187 in reported general payments places this provider in the 95th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Boston
- Otto MetzgerBoston$141.9M
- Suzanne GeorgeBoston$88.5M
- Pasi Antero JanneBoston$67.2M
- Erica MayerBoston$51.8M
- Toni ChoueiriBoston$28.3M
- Laura SpringBoston$22.9M
- Marlise LuskinBoston$18.7M
- Ana Garrido-CastroBoston$18M
- Jacob LaubachBoston$17.9M
- Geoffrey ShapiroBoston$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.